Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE Study

Back

ESC Professional Premium Access

Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE Study

Session: Left ventricular hypertrophy and hypertrophic cardiomyopathy: new findings

Topic: Infiltrative Myocardial Disease

Speaker: Doctor D. Tsilakis (GR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Dimitrios Tsilakis

(Greece)

0 follower

7 more presentations in this session

Mildly elevated left ventricular outflow tract gradients are associated with increased short term mortality in inpatients without septal hypertrophy

Speaker: Doctor S. Khoury (Tel Aviv, IL)

Endomyocardial biopsy in the diagnosis of cardiac sarcoidosis

Speaker: Ms H. Malkonen (Helsinki, FI)

Health-related quality of life disparity in cardiac sarcoidosis versus other myocardial diseases

Speaker: Mrs J. Raak-Tarkiainen (Helsinki, FI)

Health-related quality of life and prognosis in cardiac sarcoidosis

Speaker: Mrs J. Raak-Tarkiainen (Helsinki, FI)

The role of 18fluorine-fluorodeoxyglucose positron emission tomography in the diagnosis, follow-up, and regulation of treatment in patients with cardiac sarcoidosis.

Speaker: Doctor E. Bobbio (Gothenburg, SE)

Access the full session

Left ventricular hypertrophy and hypertrophic cardiomyopathy: new findings

Speakers: Doctor D. Tsilakis, Doctor S. Khoury, Ms H. Malkonen, Mrs J. Raak-Tarkiainen, Mrs J. Raak-Tarkiainen...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources